SK Bioscience Snaps Up IDT Biologika To Accelerate Growth
'Perfect Fit', New Capabilities
SK Bioscience’s acquisition of top 10 CDMO marks first major acquisition as part of its growth acceleration strategy and the biggest such investment so far by a Korean vaccines firm. Execs say deal is aligned with SK Group’s wider moves to 'rebalance' its businesses.
